Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Oragenics (OGEN)

Oragenics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:OGEN
DateTimeSourceHeadlineSymbolCompany
22/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
22/05/202413:00GlobeNewswire Inc.Oragenics Appoints William “Frank” Peacock MD as Chief Clinical OfficerAMEX:OGENOragenics Inc
17/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
17/05/202413:00GlobeNewswire Inc.Oragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineAMEX:OGENOragenics Inc
16/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
16/05/202413:00GlobeNewswire Inc.Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialAMEX:OGENOragenics Inc
15/05/202418:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OGENOragenics Inc
07/05/202413:14Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
07/05/202413:00GlobeNewswire Inc.Oragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaAMEX:OGENOragenics Inc
19/04/202422:50Business WireOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsAMEX:OGENOragenics Inc
01/04/202414:05Business WireOragenics, Inc. Files 10K and Provides Company UpdateAMEX:OGENOragenics Inc
18/03/202411:00Business WireOragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating ConcussionAMEX:OGENOragenics Inc
06/03/202421:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:OGENOragenics Inc
05/03/202412:45Business WireOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
01/03/202421:04Business WireOragenics Announces Closing of Public OfferingAMEX:OGENOragenics Inc
29/02/202421:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
28/02/202414:03Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
28/02/202402:25Business WireOragenics Announces Pricing of Public OfferingAMEX:OGENOragenics Inc
27/02/202422:09Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:OGENOragenics Inc
27/02/202422:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
27/02/202421:33Business WireOragenics Announces Proposed Public OfferingAMEX:OGENOragenics Inc
13/02/202401:06Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:OGENOragenics Inc
12/02/202421:45Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
12/02/202421:41Business WireOragenics, Inc. Announces Leadership TransitionAMEX:OGENOragenics Inc
07/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
07/02/202413:00Business WireOragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementAMEX:OGENOragenics Inc
05/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
05/02/202413:00Business WireOragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
23/01/202422:34Business WireOragenics Announces Termination of At-The-Market Offering ProgramAMEX:OGENOragenics Inc
23/01/202422:18Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
 Showing the most relevant articles for your search:AMEX:OGEN